Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $54.5 million.

  • Corcept Therapeutics' Cash from Operations fell 2566.68% to $54.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.4 million, marking a year-over-year increase of 1335.93%. This contributed to the annual value of $198.1 million for FY2024, which is 5591.04% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Cash from Operations of $54.5 million as of Q3 2025, which was down 2566.68% from $43.9 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Cash from Operations peaked at $73.3 million during Q3 2024, and registered a low of $5.1 million during Q1 2025.
  • Over the past 5 years, Corcept Therapeutics' median Cash from Operations value was $41.2 million (recorded in 2024), while the average stood at $37.7 million.
  • Per our database at Business Quant, Corcept Therapeutics' Cash from Operations tumbled by 8236.79% in 2023 and then skyrocketed by 91630.71% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Cash from Operations (Quarter) stood at $49.4 million in 2021, then plummeted by 32.45% to $33.4 million in 2022, then crashed by 82.37% to $5.9 million in 2023, then surged by 916.31% to $59.8 million in 2024, then dropped by 8.94% to $54.5 million in 2025.
  • Its last three reported values are $54.5 million in Q3 2025, $43.9 million for Q2 2025, and $5.1 million during Q1 2025.